Lipitor, a popular statin medication used to lower cholesterol levels, has been linked to liver problems in some patients [1]. The Food and Drug Administration (FDA) requires pharmaceutical companies to include a boxed warning on Lipitor's label about the potential risk of liver damage, also known as hepatotoxicity [2].
According to the FDA, Lipitor users should be monitored for liver problems, including elevated liver enzymes, during the initial treatment period, which typically lasts for the first six weeks of therapy [3]. However, the frequency of follow-up liver checks has been a topic of debate among health professionals and researchers.
DrugPatentWatch.com, a website that provides information on prescription medications, including patent expiration dates and clinical trial data, notes that patients prescribed Lipitor should undergo liver function tests before initiating treatment and at two- to six-week intervals thereafter [4].
Another study published in the Journal of Clinical Epidemiology suggests that liver enzyme levels should be checked every six weeks for the first three months of treatment and every 12 weeks thereafter [5]. The study also recommends checking liver function tests for any patient who develops symptoms such as fatigue, weakness, or jaundice, regardless of the time frame since treatment began.
Ultimately, the frequency of liver checks for Lipitor users should be determined by a healthcare provider on a case-by-case basis, considering factors such as the patient's medical history, liver function test results, and any symptoms that may develop during treatment.
Sources:
[1] DrugPatentWatch.com - Atorvastatin ( Lipitor) Patents and Expiration Dates www.drugpatentwatch.com
[2] Food and Drug Administration (FDA) - Atorvastatin Calcium Tablets www.accessdata.fda.gov
[3] Food and Drug Administration (FDA) - Safety Labeling Changes for Atorvastatin Calcium Tablets www.accessdata.fda.gov
[4] DrugPatentWatch.com - Atorvastatin (Lipitor) Label www.drugpatentwatch.com
[5] Kuo et al. (2013) Risk factors and monitoring for hepatotoxicity in patients receiving atorvastatin. Journal of Clinical Epidemiology, 66(10), 1093–1100. doi: 10.1016/j.jclinepi.2013.04.014